By: Reynald Castañeda
Novartis, in an effort to “evolve” its global development organization, is set to exit a technical research and development site in San Diego, the Swiss …
Reynald Castaneda is a journalist for Endpoints News, a leading source for biotech news and analysis. With a focus on the pharmaceutical and biotech industry, Reynald covers a wide range of topics including drug development, clinical trials, mergers and acquisitions, and market trends. His articles provide in-depth insights and updates on the latest developments in the biotech world.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Reynald Castaneda's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly pharmaceutical companies' developments, mergers & acquisitions, drug development, clinical trials. His articles often include press releases and cited data.
To effectively reach out to Reynald, consider providing detailed insights into newsworthy scientific advancements in drug development or clinical trial results. Additionally, if you have expertise related to mergers and acquisitions within the pharmaceutical industry or can provide valuable analysis of healthcare-related data trends, it could be of interest to him.
As his geographic focus is not specified but given that many news items are international in scope with global pharma companies involved, pitching internationally relevant content would likely align best with his coverage areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .